

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection	This study was performed using Google Earth Engine Code Editor, SWAT rev.681, R 4.2.0, QGIS 3.22.8, MATLAB 2022a, AMALGAM, PAWN, and QSWAT3.
Data analysis	Codes from this study, including Google Earth Engine scripts and those to reproduce figures and analyses, are available from GitHub at <a href="https://github.com/Danmyers901/Calibration/tree/master/Landcover">https://github.com/Danmyers901/Calibration/tree/master/Landcover</a> .

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Data from this study, including the LULC images, water quality data, and model outputs from each case, are available from Mendeley Data at <https://doi.org/10.17632/bbb9xbpv22.2>.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

### Reporting on sex and gender

Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data where this information has been collected, and consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.

### Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

### Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

### Ethics oversight

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

### Study description

We used the Dynamic World real-time landcover dataset with water quality and hydrologic models representing a range of complexity. This allowed us to evaluate how the models work with non-growing season landcover data, identify sensitivities, and discuss future research opportunities.

### Research sample

Our data included water quality measurements from the United States National Park Service, and remotely sensed landcover images from Dynamic World, for 37 current (+18 inactive) monitoring sites near Washington, D.C., USA.

Norris, M., Pieper, J., Watts, T. & Cattani, A. National Capital Region Network Inventory and Monitoring Program Water Chemistry and Quantity Monitoring Protocol Version 2.0 Water chemistry, nutrient dynamics, and surface water dynamics vital signs. Natural Resource Report NPS/NCRN/NRR—2011/423 (2011).

Brown, C. F. et al. Dynamic World, Near real-time global 10m land use land cover mapping. *Scientific Data* 2022 9:1 9, 1–17 (2022).

### Sampling strategy

Sample sites were chosen for having long-term water quality records.

### Data collection

Water quality data were collected from 2005–2018 for monitoring sites in National Parks by the United States National Park Service. Specific conductance was measured using a YSI sensor. Dynamic World data was downloaded from Google Earth Engine Code editor by the authors.

### Timing and spatial scale

National Park Service water quality data were collected monthly from 2005–2013, quarterly from 2014–2017, and bi-monthly in 2018. Median values over time were used to represent water quality tendencies.

### Data exclusions

18 inactive monitoring sites were excluded from the water quality analyses because they had an incomplete record of data.

### Reproducibility

We have made our Google Earth Engine scripts available, as well as our R scripts to reproduce analyses and figures, so that researchers can reproduce our study and verify our findings. All of our water quality data, landcover data, and models are publicly available.

### Randomization

Dynamic World images were allocated into growing season (spring equinox to autumn equinox) and non-growing season (autumn equinox to spring equinox) following instructions in Brown et al. 2022.

Brown, C. F. et al. Dynamic World, Near real-time global 10m land use land cover mapping. *Scientific Data* 2022 9:1 9, 1–17 (2022).

## Blinding

No blinding was used in the study because the SWAT model development required careful examination of input data to ensure processes were being adequately represented.

Did the study involve field work?  Yes  No

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	Antibodies
<input type="checkbox"/>	Eukaryotic cell lines
<input type="checkbox"/>	Palaeontology and archaeology
<input type="checkbox"/>	Animals and other organisms
<input type="checkbox"/>	Clinical data
<input type="checkbox"/>	Dual use research of concern

### Methods

n/a	Involved in the study
<input type="checkbox"/>	ChIP-seq
<input type="checkbox"/>	Flow cytometry
<input type="checkbox"/>	MRI-based neuroimaging

## Antibodies

### Antibodies used

Describe all antibodies used in the study; as applicable, provide supplier name, catalog number, clone name, and lot number.

### Validation

Describe the validation of each primary antibody for the species and application, noting any validation statements on the manufacturer's website, relevant citations, antibody profiles in online databases, or data provided in the manuscript.

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

### Cell line source(s)

State the source of each cell line used and the sex of all primary cell lines and cells derived from human participants or vertebrate models.

### Authentication

Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.

### Mycoplasma contamination

Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

### Commonly misidentified lines (See [ICLAC](#) register)

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

## Palaeontology and Archaeology

### Specimen provenance

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information). Permits should encompass collection and, where applicable, export.

### Specimen deposition

Indicate where the specimens have been deposited to permit free access by other researchers.

### Dating methods

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

### Ethics oversight

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

### Laboratory animals

*For laboratory animals, report species, strain and age OR state that the study did not involve laboratory animals.*

### Wild animals

*Provide details on animals observed in or captured in the field; report species and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.*

### Reporting on sex

*Indicate if findings apply to only one sex; describe whether sex was considered in study design, methods used for assigning sex. Provide data disaggregated for sex where this information has been collected in the source data as appropriate; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex-based analyses where performed, justify reasons for lack of sex-based analysis.*

### Field-collected samples

*For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.*

### Ethics oversight

*Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.*

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

### Clinical trial registration

*Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.*

### Study protocol

*Note where the full trial protocol can be accessed OR if not available, explain why.*

### Data collection

*Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.*

### Outcomes

*Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.*

## Dual use research of concern

Policy information about [dual use research of concern](#)

### Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No	Yes
<input type="checkbox"/>	<input type="checkbox"/> Public health
<input type="checkbox"/>	<input type="checkbox"/> National security
<input type="checkbox"/>	<input type="checkbox"/> Crops and/or livestock
<input type="checkbox"/>	<input type="checkbox"/> Ecosystems
<input type="checkbox"/>	<input type="checkbox"/> Any other significant area

## Experiments of concern

Does the work involve any of these experiments of concern:

No  Yes

- Demonstrate how to render a vaccine ineffective
- Confer resistance to therapeutically useful antibiotics or antiviral agents
- Enhance the virulence of a pathogen or render a nonpathogen virulent
- Increase transmissibility of a pathogen
- Alter the host range of a pathogen
- Enable evasion of diagnostic/detection modalities
- Enable the weaponization of a biological agent or toxin
- Any other potentially harmful combination of experiments and agents

## ChIP-seq

### Data deposition

- Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

#### Data access links

*May remain private before publication.*

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

#### Files in database submission

Provide a list of all files available in the database submission.

#### Genome browser session (e.g. [UCSC](#))

Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

## Methodology

### Replicates

Describe the experimental replicates, specifying number, type and replicate agreement.

### Sequencing depth

Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.

### Antibodies

Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.

### Peak calling parameters

Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.

### Data quality

Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.

### Software

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

## Methodology

### Sample preparation

Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.

### Instrument

Identify the instrument used for data collection, specifying make and model number.

## Software

Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.

## Cell population abundance

Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.

## Gating strategy

Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

## Design type

Indicate task or resting state; event-related or block design.

## Design specifications

Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.

## Behavioral performance measures

State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

### Acquisition

## Imaging type(s)

Specify: functional, structural, diffusion, perfusion.

## Field strength

Specify in Tesla

## Sequence &amp; imaging parameters

Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.

## Area of acquisition

State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.

## Diffusion MRI

Used

Not used

### Preprocessing

## Preprocessing software

Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).

## Normalization

If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.

## Normalization template

Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.

## Noise and artifact removal

Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).

## Volume censoring

Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

### Statistical modeling & inference

## Model type and settings

Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).

## Effect(s) tested

Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.

Specify type of analysis:  Whole brain  ROI-based  BothStatistic type for inference  
(See [Eklund et al. 2016](#))

Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.

## Correction

Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).

## Models &amp; analysis

n/a Involved in the study

 Functional and/or effective connectivity Graph analysis Multivariate modeling or predictive analysis

Functional and/or effective connectivity

*Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).*

Graph analysis

*Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).*

Multivariate modeling and predictive analysis

*Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.*